Cristina Saavedra

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 19, 2025

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

Journal: Future oncology (London, England)

Published: February 28, 2025

In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy.

In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy.

Journal: Scientific reports

Published: November 06, 2024

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Journal: The oncologist

Published: April 15, 2024

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

Journal: Cancer immunology, immunotherapy : CII

Published: March 24, 2024

Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.

Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.

Journal: The oncologist

Published: March 11, 2024

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

Journal: ESMO open

Published: March 04, 2024

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.

Journal: International journal of molecular sciences

Published: February 22, 2024

Top advances of the year: Breast cancer.

Top advances of the year: Breast cancer.

Journal: Cancer

Published: April 04, 2023

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.

Journal: Frontiers in oncology

Published: February 04, 2023

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.

Journal: Cancers

Published: December 30, 2022

Oligometastatic Disease: When Stage IV Breast Cancer Could Be "Cured".

Oligometastatic Disease: When Stage IV Breast Cancer Could Be "Cured".

Journal: Cancers

Published: August 20, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026